TRUSCREEN GROUP LIMITED logo

ASX Approves TruScreen to Official List Offer Closes 18 Dec

Listing Change14 December 2020TRUIndustrials

NZX Announcement

15 December 2020


ASX APPROVES TRUSCREEN TO OFFICIAL LIST – OFFER TO CLOSE 18

DECEMBER 2020

TruScreen Group Limited (NZX: TRU) (TruScreen or the Company) is pleased to advise that ASX has

confirmed it will admit TruScreen to the Official List of ASX subject to the satisfaction of certain conditions

precedent outlined below. TruScreen confirms that it will be able to comply with all conditions following

closure of the offer on 18 December 2020.

Conditions of Admission

• Closure of the offer under the Product Disclosure Statement (‘PDS’ or ‘Prospectus”) and completion

of the issue of at least 14,285,714 ordinary fully paid shares at an issue price of NZ$0.07.

• Confirmation that TruScreen has received cleared funds for the complete amount of the issue price

of every fully paid security issued to every successful applicant for fully paid securities under the

Prospectus

• Confirmation that TruScreen has been registered as a foreign company under the Corporations Act

2001 (Cth).

Conditions of quotation

• The issue of holding notices for shares issued, and refund money for those applicants unsuccessful

• Provision of the following documents for release to the market:

o Appendix 1C, Information Form and Checklist and Annexure 2

o PDS

o TruScreen Constitution

o Pro Forma statements of Financial Position

o Updated pro forma statement of financial position based on the actual amount raised under the

Prospectus

o A distribution schedule of the numbers of holders in each class of security to be quoted, setting

out the number and percentage holding as set out in Appendix 1A and Information Form and

Checklist

o A statement setting out the names of the 20 largest holders of each class of securities to be

quoted, including the number and percentage for each class of securities held by those holders.

As outlined in the PDS lodged with the NZX on 11 November 2020, applications can be made through the

online application portal at https://www.truscreenshareoffer.co.nz/. A copy of the registered PDS in

support of the Offer is available on the online application portal. Australian applications can be made at

www.onmarket.com.au


-ENDS-







For more information, visit www.truscreen.com or contact:


Victoria Potarina

Chief Executive Officer

victoriapotarina@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com



About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-

time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being

of women around the world.

TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the

cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary

algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by

optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with

conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for

supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries

where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico,

Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use

throughout Europe and NMPA (formerly CFDA) approved for sale in China. The global market potential for

TruScreen is significant.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.